Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.048
Buy
RSI(14)
59.732
Neutral
STOCH(KDJ)(9,3,3)
54.820
Buy
ATR(14)
0.273
High Vlolatility
CCI(14)
79.727
Neutral
Williams %R
15.349
Overbought
TRIX(12,20)
0.408
Sell
StochRSI(14)
100.000
Buy
Abeona Therapeutics Inc
ABEO5.440USD
+0.330+6.46%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
285.06MMarket Cap
3.36P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Abeona Therapeutics Inc
Currency: USD Updated: 2025-12-22Key Insights
Abeona Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 45/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 20.21.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Abeona Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Buy
Current Rating
20.214
Target Price
+294.04%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Abeona Therapeutics Inc Highlights
StrengthsRisks
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. The Company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa. Its fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. Its development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Its AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Its pipeline programs include ABO-504 (Stargardt disease), ABO-503 (X-linked retinoschisis), ABO-505 (autosomal dominant optic atrophy), UX111 (Sanfilippo Syndrome Type A (MPS IIIA)), TSHA-102 (Rett Syndrome), and TSHA-118 (Infantile Batten Disease (CLN1 Disease)).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is 3.36, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 36.22M shares, decreasing 0.03% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 687.00 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.04.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of Abeona Therapeutics Inc is 7.23, ranking 125/158 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
9.10
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
6.63
Operational Efficiency
2.86
Growth Potential
10.00
Shareholder Returns
7.58
Abeona Therapeutics Inc's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of Abeona Therapeutics Inc is 7.23, ranking 89/158 in the Pharmaceuticals industry. Its current P/E ratio is 3.36, which is 103.19% below the recent high of 6.84 and 514.35% above the recent low of -13.94.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 45/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of Abeona Therapeutics Inc is 9.00, ranking 5/158 in the Pharmaceuticals industry. The average price target for Abeona Therapeutics Inc is 19.00, with a high of 27.50 and a low of 14.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
20.214
Target Price
+294.04%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Abeona Therapeutics Inc
ABEO
7
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
AbbVie Inc
ABBV
32
1
2
3
...
34
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of Abeona Therapeutics Inc is 9.19, ranking 32/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 5.89 and the support level at 4.71, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
5.064
Buy
MA10
5.199
Buy
MA20
5.030
Buy
MA50
4.941
Buy
MA100
5.587
Sell
MA200
5.657
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of Abeona Therapeutics Inc is 7.00, ranking 44/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 79.02%, representing a quarter-over-quarter decrease of 3.97%. The largest institutional shareholder is The Vanguard, holding a total of 2.60M shares, representing 4.80% of shares outstanding, with 21.63% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Nantahala Capital Management, LLC
Adage Capital Management, L.P.
BlackRock Institutional Trust Company, N.A.
Suvretta Capital Management, LLC
Vivo Capital, LLC
Western Standard, LLC
Seshadri (Vishwas)
1
2
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of Abeona Therapeutics Inc is 4.65, ranking 84/158 in the Pharmaceuticals industry. The company's beta value is 1.12. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.12
VaR
+7.14%
240-Day Maximum Drawdown
+42.32%
240-Day Volatility
+65.43%
Return
Best Daily Return
60 days
+18.47%
120 days
+18.47%
5 years
+25.28%
Worst Daily Return
60 days
-8.30%
120 days
-10.96%
5 years
-53.67%
Sharpe Ratio
60 days
+0.41
120 days
+0.20
5 years
-0.17
Risk Assessment
Maximum Drawdown
240 days
+42.32%
3 years
+63.48%
5 years
+96.12%
Return-to-Drawdown Ratio
240 days
-0.22
3 years
+0.54
5 years
-0.19
Skewness
240 days
+1.26
3 years
-1.42
5 years
-0.73
Volatility
Realised Volatility
240 days
+65.43%
5 years
+98.64%
Standardised True Range
240 days
+5.81%
5 years
+13.00%
Downside Risk-Adjusted Return
120 days
+33.81%
240 days
+33.81%
Maximum Daily Upside Volatility
60 days
+78.18%
Maximum Daily Downside Volatility
60 days
+41.24%
Liquidity
Average Turnover Rate
60 days
+1.74%
120 days
+2.60%
5 years
--
Turnover Deviation
20 days
-3.99%
60 days
+16.04%
120 days
+73.48%
Peer Comparison
Pharmaceuticals
Abeona Therapeutics Inc
ABEO
7.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.84 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.71 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
CPRX
8.63 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Abeona Therapeutics Inc?
The TradingKey Stock Score provides a comprehensive assessment of Abeona Therapeutics Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Abeona Therapeutics Inc’s performance and outlook.
How do we generate the financial health score of Abeona Therapeutics Inc?
To generate the financial health score of Abeona Therapeutics Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Abeona Therapeutics Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Abeona Therapeutics Inc.
How do we generate the company valuation score of Abeona Therapeutics Inc?
To generate the company valuation score of Abeona Therapeutics Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Abeona Therapeutics Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Abeona Therapeutics Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Abeona Therapeutics Inc.
How do we generate the earnings forecast score of Abeona Therapeutics Inc?
To calculate the earnings forecast score of Abeona Therapeutics Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Abeona Therapeutics Inc’s future.
How do we generate the price momentum score of Abeona Therapeutics Inc?
When generating the price momentum score for Abeona Therapeutics Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Abeona Therapeutics Inc’s prices. A higher score indicates a more stable short-term price trend for Abeona Therapeutics Inc.
How do we generate the institutional confidence score of Abeona Therapeutics Inc?
To generate the institutional confidence score of Abeona Therapeutics Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Abeona Therapeutics Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Abeona Therapeutics Inc.
How do we generate the risk management score of Abeona Therapeutics Inc?
To assess the risk management score of Abeona Therapeutics Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Abeona Therapeutics Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Abeona Therapeutics Inc.
